Stiles Financial Services Inc
Position in REGN — Regeneron Pharmaceuticals, Inc.
CIK 1904832
EDINA, MN
Position in REGN
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$2,222,296
-$597,840 QoQ
Shares Held
3,564
-2.4% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.57%
of 13F equity value
Holder Rank
#501
of 1,322 holders
Holding Since
Dec 2022
15 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Stiles Financial Services Inc holds $2,222,296 across 1 Biotechnology name. REGN ranks #1 (100.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
This page
|
3,564 | $2,222,296 |
All Filings in REGN
Export CSV
15 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,222,296 | 3,564 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $2,820,136 | 3,650 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $3,095,970 | 4,011 | Shares | Sole | 2026-02-03 | |
| 2025-09-30 | $2,447,561 | 4,353 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $2,287,950 | 4,358 | Shares | Sole | 2025-07-24 | |
| 2025-03-31 | $2,597,806 | 4,096 | Shares | Sole | 2025-04-22 | |
| 2024-12-31 | $2,775,237 | 3,896 | Shares | Sole | 2025-01-28 | |
| 2024-09-30 | $3,607,855 | 3,432 | Shares | Sole | 2024-10-31 | |
| 2024-06-30 | $3,513,593 | 3,343 | Shares | Sole | 2024-08-01 | |
| 2024-03-31 | $3,156,004 | 3,279 | Shares | Sole | 2024-04-30 | |
| 2023-12-31 | $2,663,853 | 3,033 | Shares | Sole | 2024-01-26 | |
| 2023-09-30 | $2,221,169 | 2,699 | Shares | Sole | 2023-11-08 | |
| 2023-06-30 | $1,398,278 | 1,946 | Shares | Sole | 2023-07-21 | |
| 2023-03-31 | $1,129,796 | 1,375 | Shares | Sole | 2023-05-11 | |
| 2022-12-31 | $714,275 | 990 | Shares | Sole | 2023-01-27 | |
| No filing history on record for this holder in this stock. | ||||||